Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Component and Couple Analysis of Cancer Communications
Component and Couple Analysis of Cancer Communications
Status: Enrolling
Updated:  4/21/2016
University of Wisconsin
mi
from
Madison, WI
Component and Couple Analysis of Cancer Communications
Component and Couple Analysis of Cancer Communications
Status: Enrolling
Updated: 4/21/2016
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Magnetic Resonance Study of Liver in Chemotherapy
Magnetic Resonance Study of Liver in Chemotherapy
Status: Enrolling
Updated:  4/25/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Magnetic Resonance Study of Liver in Chemotherapy
Magnetic Resonance Study of Liver in Chemotherapy
Status: Enrolling
Updated: 4/25/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Methylphenidate for Cancer-Related Fatigue
Methylphenidate for Cancer-Related Fatigue: A Pilot N-of-1 Study
Status: Enrolling
Updated:  4/25/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Methylphenidate for Cancer-Related Fatigue
Methylphenidate for Cancer-Related Fatigue: A Pilot N-of-1 Study
Status: Enrolling
Updated: 4/25/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Methylphenidate for Cancer-Related Fatigue
Methylphenidate for Cancer-Related Fatigue: A Pilot N-of-1 Study
Status: Enrolling
Updated:  4/25/2016
Boston Children's Hospital
mi
from
Boston, MA
Methylphenidate for Cancer-Related Fatigue
Methylphenidate for Cancer-Related Fatigue: A Pilot N-of-1 Study
Status: Enrolling
Updated: 4/25/2016
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery
A "Bathing Bundle" Regimen to Reduce the Risk of Gynecological Surgical Site Infection
Status: Enrolling
Updated:  4/26/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery
A "Bathing Bundle" Regimen to Reduce the Risk of Gynecological Surgical Site Infection
Status: Enrolling
Updated: 4/26/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated:  4/27/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated: 4/27/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated:  4/27/2016
Clinical Research Facility
mi
from
Detroit, MI
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated: 4/27/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated:  4/27/2016
Clinical Research Facility
mi
from
Hackensack, NJ
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated: 4/27/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated:  4/27/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated: 4/27/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated:  4/27/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated: 4/27/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated:  4/27/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors
Status: Enrolling
Updated: 4/27/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety Study on the Transfer of the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma
Phase I, Initial Safety/Toxicity Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdCUCD40L) to Patients With Stage III or IV Esophageal Carcinoma
Status: Enrolling
Updated:  5/2/2016
The Valley Hospital
mi
from
Ridgewood, NJ
Safety Study on the Transfer of the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma
Phase I, Initial Safety/Toxicity Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdCUCD40L) to Patients With Stage III or IV Esophageal Carcinoma
Status: Enrolling
Updated: 5/2/2016
The Valley Hospital
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
Safety Study on the Transfer of the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma
Phase I, Initial Safety/Toxicity Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdCUCD40L) to Patients With Stage III or IV Esophageal Carcinoma
Status: Enrolling
Updated:  5/2/2016
Weill Medical College of Cornell University
mi
from
New York, NY
Safety Study on the Transfer of the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma
Phase I, Initial Safety/Toxicity Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdCUCD40L) to Patients With Stage III or IV Esophageal Carcinoma
Status: Enrolling
Updated: 5/2/2016
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/2/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/2/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/2/2016
Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service
mi
from
Scottsdale, AZ
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/2/2016
Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/2/2016
Sarah Cannon Research Institute Sarah Cannon Research Instit
mi
from
Nashville, TN
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/2/2016
Sarah Cannon Research Institute Sarah Cannon Research Instit
mi
from
Nashville, TN
Click here to add this to my saved trials
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/2/2016
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/2/2016
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Sacramento, CA
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Santa Monica, CA
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Washington,
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Tampa, FL
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Chicago, IL
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Detroit, MI
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Las Vegas, NV
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Hackensack, NJ
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Huntersville, NC
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Huntersville, NC
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Portland, OR
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Memphis, TN
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Houston, TX
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
Cedars Sinai Medical Center SC - 4
mi
from
Los Angeles, CA
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
Cedars Sinai Medical Center SC - 4
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
Stanford University Medical Center Stanford Cancer Center (3)
mi
from
Stanford, CA
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
Stanford University Medical Center Stanford Cancer Center (3)
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
H. Lee Moffitt Cancer Center & Research Institute Dept.of H.LeeMoffittCC&RI(1)
mi
from
Tampa, FL
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
H. Lee Moffitt Cancer Center & Research Institute Dept.of H.LeeMoffittCC&RI(1)
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
mi
from
Houston, TX
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
Novartis Investigative Site
mi
from
Bruxelles,
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
Novartis Investigative Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Status: Enrolling
Updated:  5/2/2016
Mayo Clinic
mi
from
Jacksonville, FL
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Status: Enrolling
Updated: 5/2/2016
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Status: Enrolling
Updated:  5/2/2016
Veterans Affairs Hospital
mi
from
Kansas City, MO
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Status: Enrolling
Updated: 5/2/2016
Veterans Affairs Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Status: Enrolling
Updated:  5/2/2016
New York Presbyterian Hospital - Columbia University Medical Center
mi
from
New York, NY
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Status: Enrolling
Updated: 5/2/2016
New York Presbyterian Hospital - Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Status: Enrolling
Updated:  5/2/2016
Centre Hospitalier Universitaire
mi
from
Nantes,
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Status: Enrolling
Updated: 5/2/2016
Centre Hospitalier Universitaire
mi
from
Nantes,
Click here to add this to my saved trials
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated:  5/3/2016
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated: 5/3/2016
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated:  5/3/2016
Columbia University Medical Center
mi
from
New York, NY
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated: 5/3/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated:  5/3/2016
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated: 5/3/2016
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated:  5/3/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Status: Enrolling
Updated: 5/3/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated:  5/3/2016
Clinical Research Facility
mi
from
Aurora, CO
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated: 5/3/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated:  5/3/2016
Clinical Research Facility
mi
from
St. Petersburg, FL
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated: 5/3/2016
Clinical Research Facility
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated:  5/3/2016
Clinical Research Facility
mi
from
Tampa, FL
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated: 5/3/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated:  5/3/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated: 5/3/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated:  5/3/2016
Clinical Research Facility
mi
from
Cincinatti, OH
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated: 5/3/2016
Clinical Research Facility
mi
from
Cincinatti, OH
Click here to add this to my saved trials
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated:  5/3/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated: 5/3/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated:  5/3/2016
mi
from
Nasheville, TN
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status: Enrolling
Updated: 5/3/2016
mi
from
Nasheville, TN
Click here to add this to my saved trials